ArticleDiabetes, metabolic syndrome and obesity : targets and therapy2013
Clinical utility of phentermine/topiramate (Qsymia™) combination for the treatment of obesity.
Article in Diabetes, metabolic syndrome and obesity : targets and therapy, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 53 citations in OpenAlex.
- Evaluation of the efficacy and safety of controlled-release phentermine/topiramate in adults with obesity in Korea: A randomized, double-blind, placebo-controlled, phase 4 trial (QUEEN's study).Diabetes, obesity & metabolism · 2025Trial
- Real-World Evidence for Existing Anti-Obesity Therapies-The Realities of Treatment Adherence, Tolerability, Access and Patient Satisfaction.Diabetes, obesity & metabolism · 2026Review
- Obesity pillars roundtable: Better together - combined obesity medicine and metabolic surgery care for the treatment of obesity.Obesity pillars · 2026Article
- Risk Factors and Management Strategies for Antipsychotic-Induced Weight Gain: A Prescriptive Review for Clinicians.Focus (American Psychiatric Publishing) · 2025Review
- Addressing the challenge of obesity in primary care: a review of effective interventions and implementation strategies.Diabetology & metabolic syndrome · 2025Review
- A Review of Amylin Peptide Receptor Activators for Obesity Pharmacotherapy.Current drug targets · 2025Review
- Drug Repurposing: A Leading Strategy for New Threats and Targets.ACS pharmacology & translational science · 2024Review
- Topiramate (Topamax): Evolving Role in Weight Reduction Management: A Narrative Review.Life (Basel, Switzerland) · 2023Review
- Recent advancements in pharmacological strategies to modulate energy balance for combating obesity.RSC medicinal chemistry · 2023Review
- Unraveling Obesity: Transgenerational Inheritance, Treatment Side Effects, Flavonoids, Mechanisms, Microbiota, Redox Balance, and Bioavailability-A Narrative Review.Antioxidants (Basel, Switzerland) · 2023Review
- Phytochemical Combination (Nutrients · 2022Article
- Chinese herbal medicine is associated with higher body weight reduction than liraglutide among the obese population: A real-world comparative cohort study.Frontiers in pharmacology · 2022Article
- Combined Anti-Adipogenic Effects of Hispidulin andBiomolecules · 2021Article
- New Incretin Combination Treatments under Investigation in Obesity and Metabolism: A Systematic Review.Pharmaceuticals (Basel, Switzerland) · 2021Review
- Brain-gut-microbiome interactions in obesity and food addiction.Nature reviews. Gastroenterology & hepatology · 2020Review
- A Systematic Review of the European Rapid Alert System for Food and Feed: Tendencies in Illegal Food Supplements for Weight Loss.Frontiers in pharmacology · 2020Review
- Incorporating Weight Loss Medications Into Hepatology Practice for Nonalcoholic Steatohepatitis.Hepatology (Baltimore, Md.) · 2019Review
- Combined effects ofFood science and biotechnology · 2019Article
- Combined Amylin/GLP-1 pharmacotherapy to promote and sustain long-lasting weight loss.Scientific reports · 2019Article
- Obesity Management: Clinical Review and Update of the Pharmacologic Treatment Options.Federal practitioner : for the health care professionals of the VA, DoD, and PHS · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Qsymia™ (Vivus Inc, Mountain View, CA, USA), a combination of phentermine and delayed-release topiramate, has been available in the US since September 2012 for the treatment of obesity. Phentermine is an anorexigenic agent, which is approved for the short-term treatment of obesity, while topiramate is approved for nonweight loss indications - seizure disorders and migraine prophylaxis. The amount of weight loss achieved with combination therapy is of a greater magnitude than what could be achieved with either agent alone. Adverse events that occur with the combination therapy are in line with the known side effect profiles of the constituent drugs; teratogenicity, a slight increase in heart rate, psychiatric and cognitive adverse effects, and metabolic acidosis are concerns.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.